The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Phase II Trial of Tideglusib in Alzheimer's Disease
Abstract
BACKGROUND: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD). OBJECTIVE: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. METHODS: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 weeks. The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints. RESULTS: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries. There were no statistically significant differences between either active and placebo arms in the efficacy variables. However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients. Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency. Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. However, given the non-linear dose response, especially in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“The clinical studies in patients with mild-to-moderate AD (NCT01350362, NCT00948259) or PSP (NCT01049399) patients treated with tideglusib were negative on the clinical outcomes [218]; however, a subgroup analysis of PSP patients showed reduced brain atrophy [219].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [218]
In the citing paper
“However, a phase 2 trial in mild to moderate AD did not demonstrate any reduction in rate of cognitive or functional decline as compared to placebo (Lovestone et al., 2015)”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Lovestone et al., 2015
In the citing paper
“Tideglusib, a small-molecule GSK3β inhibitor, failed to improve cognition in a phase 2 clinical study, and CSF levels of Aβ42, total tau, and pTau181 were not altered, resulting in failure of the trial [175,176].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [176]
In the citing paper
“In a larger phase II study, tideglusib treatment was associated with significant cognitive improvement and a reduction in CSF levels of β-secretase in a subgroup of patients with mild AD122. However, when the entire study cohort was analysed, tideglusib was found to be well tolerated but produced no significant improvements122.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [122]
In the citing paper
“Another GSK-3 inhibitor, tideglusib, did not meet phase 2 clinical endpoints in patients with mild and moderate AD.80”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [80]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,535
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Glycogen synthase kinase-3 signaling in Alzheimer’s disease
Lauretti, E., Dincer, O., & Praticò, D. (2020) · Biochimica et biophysica acta. Molecular cell research · doi:10.1016/j.bbamcr.2020.118664 · Cited by 543
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 612
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
“The clinical studies in patients with mild-tomoderate AD (NCT01350362, NCT00948259) or PSP (NCT01049399) patients treated with tideglusib were negative on the clinical outcomes [218]; however, a subgroup analysis of PSP patients showed reduced brain atrophy [219].”
ResultVerdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 509
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 462
The multifaceted role of Nrf2 in mitochondrial function
Holmström, K. M., Kostov, R. V., & Dinkova-Kostova, A. T. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.10.002 · Cited by 368
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link
Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301
Dendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19
Hu, Q., Xiong, Y., Zhu, G., Zhang, Y., Zhang, Y., Huang, P. C., & Ge, G. (2022) · MedComm · doi:10.1002/mco2.151 · Cited by 270
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases
Wu, M., Zhang, M., Yin, X., Chen, K., Hu, Z., Zhou, Q., Cao, X., Chen, Z., & Liu, D. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00270-1 · Cited by 241
Multifaceted Roles of GSK‐3 in Cancer and Autophagy‐Related Diseases
Mancinelli, R., Carpino, G., Petrungaro, S., Mammola, C. L., Tomaipitinca, L., Filippini, A., Facchiano, A., Ziparo, E., & Giampietri, C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4629495 · Cited by 242
Rosenzweig, N., Dvir-Szternfeld, R., Tsitsou-Kampeli, A., Keren‐Shaul, H., Ben-Yehuda, H., Weill-Raynal, P., Cahalon, L., Kertser, A., Baruch, K., Amit, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08352-5 · Cited by 230
Tau in neurodegenerative disease
Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
Xia, Y., Prokop, S., & Giasson, B. I. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00460-5 · Cited by 227
Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases
George, M., Tharakan, M., Culberson, J. W., Reddy, A. P., & Reddy, P. H. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101756 · Cited by 216
Promotion of natural tooth repair by small molecule GSK3 antagonists
Neves, V. C. M., Babb, R., Chandrasekaran, D., & Sharpe, P. T. (2017) · Scientific Reports · doi:10.1038/srep39654 · Cited by 204
Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 207
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 190
Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S., Du, M., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 189
McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272571 · Cited by 167
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Walz, A. L., Ugolkov, A. V., Chandra, S., Kozikowski, A. P., Carneiro, B. A., O’Halloran, T. V., Giles, F. J., Billadeau, D. D., & Mazar, A. P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2240 · Cited by 168
Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159
Glia Crosstalk in Neuroinflammatory Diseases
Bernaus, A., Blanco, S., & Sevilla, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00209 · Cited by 157
An Overview on the Clinical Development of Tau-Based Therapeutics
Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156
GSK3: A Kinase Balancing Promotion and Resolution of Inflammation
Hoffmeister, L., Diekmann, M., Brand, K., & Huber, R. (2020) · Cells · doi:10.3390/cells9040820 · Cited by 149
Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease
Kerr, F., Sofola-Adesakin, O., Ivanov, D. K., Gatliff, J., Perez‐Nievas, B. G., Bertrand, H. C., Martinez, P., Callard, R., Snoeren, I., Cochemé, H. M., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006593 · Cited by 147
Lithium and Therapeutic Targeting of GSK-3
Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 152
Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101716 · Cited by 146
Neurogenesis After Stroke: A Therapeutic Perspective
Rahman, A. A., Amruta, N., Pinteaux, E., & Bix, G. J. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00841-w · Cited by 147
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 142
Vaquer‐Alicea, J., Diamond, M. I., & Joachimiak, Ł. A. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02301-7 · Cited by 139
Moreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 137
Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward
Ruiz, S. M. A., & Eldar-Finkelman, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.792364 · Cited by 133
Disruption of axonal transport in neurodegeneration
Berth, S. H., & Lloyd, T. E. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168554 · Cited by 135
Recent advances in understanding the cellular roles of GSK-3
Cormier, K. W., & Woodgett, J. R. (2017) · F1000Research · doi:10.12688/f1000research.10557.1 · Cited by 121
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 129
Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer’s Disease: A Hypothesis
Sonawane, S. K., & Chinnathambi, S. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1111-5 · Cited by 115
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges
Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 116
De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110
Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer’s Disease
Gong, C., Dai, C., Liu, F., & Iqbal, K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.837649 · Cited by 109
Li, T., Lu, L., Pember, E., Li, X., Zhang, B., & Zhu, Z. (2022) · Cells · doi:10.3390/cells11121925 · Cited by 109
Habtemariam, S. (2019) · Molecules · doi:10.3390/molecules24081519 · Cited by 115
Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration
Clark, A. R., & Ohlmeyer, M. H. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.016 · Cited by 108
Zhou, J., Ahmad, F., Parikh, S. S., Hoffman, N. E., Rajan, S., Verma, V. K., Song, J., Yuan, A., Shanmughapriya, S., Guo, Y., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308544 · Cited by 105
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 113
How Can Insulin Resistance Cause Alzheimer’s Disease?
Yoon, J. H., Hwang, J., Son, S. U., Choi, J., You, S.-W., Park, H., Cha, S.-Y., & Maeng, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043506 · Cited by 106
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders
Eira, J., Silva, C. S., Sousa, M. M., & Liz, M. A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.007 · Cited by 109
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration
Rippin, I., & Eldar-Finkelman, H. (2021) · Cells · doi:10.3390/cells10020262 · Cited by 102
Wagner, F. F., Benajiba, L., Campbell, A. J., Weïwer, M., Sacher, J. R., Gale, J. P., Ross, L. S., Puissant, A., Alexe, G., Conway, A. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8460 · Cited by 100
Ryan, P., Patel, B., Makwana, V., Jadhav, H. R., Kiefel, M. J., Davey, A. K., Reekie, T. A., Rudrawar, S., & Kassiou, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00185 · Cited by 101
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers
Sonawane, S. K., Balmik, A. A., Boral, D., Ramasamy, S., & Chinnathambi, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108119 · Cited by 98
Griebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97
Şahin, İ., Eturi, A., Souza, A. O., Pamarthy, S., Tavora, F., Giles, F. J., & Carneiro, B. A. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595283 · Cited by 99
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 97
Pathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 111
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
New Features about Tau Function and Dysfunction
Medina, M., Hernández, F., & Ávila, J. (2016) · Biomolecules · doi:10.3390/biom6020021 · Cited by 92
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 92
The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy
Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 98
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 87
Drug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86
An expanding GSK3 network: implications for aging research
Souder, D. C., & Anderson, R. M. (2019) · GeroScience · doi:10.1007/s11357-019-00085-z · Cited by 89
Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders
Tastan, B., Arioz, B. I., & Genç, Ş. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865772 · Cited by 87
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 88
Premise and peril of Wnt signaling activation through GSK-3β inhibition
Law, S. M., & Zheng, J. (2022) · iScience · doi:10.1016/j.isci.2022.104159 · Cited by 87
Edderkaoui, M., Chheda, C., Soufi, B., Zayou, F., Hu, R. W., Ramanujan, V. K., Pan, X., Boros, L. G., Tajbakhsh, J., Madhav, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.028 · Cited by 84
Yao, H., Uras, G., Zhang, P., Xu, S., Yin, Y., Liu, J., Qin, S., Li, X., Allen, S., Bai, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00160 · Cited by 83
Two decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H. J., Han, Y., Kong, L. D., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 84
Microvascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 85
Rudnitskaya, E. A., Muraleva, N. A., Maksimova, K. Y., Владимировна, К. Е., Kolosova, N. G., & Stefanova, N. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150161 · Cited by 82
Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?
Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
Hayes, L. R., & Kaláb, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01260-5 · Cited by 86
NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases
Cores, Á., Piquero, M., Villacampa, M., Leon, R. M., & Menéndez, J. C. (2020) · Biomolecules · doi:10.3390/biom10060904 · Cited by 86
Wu, X., Piña-Crespo, J., Zhang, Y., Chen, X., & Xu, H. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.220313 · Cited by 82
Zhao, Y., Chen, X., Wu, Y., Wang, Y., Li, Y., & Xiang, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00140 · Cited by 79
Natural and synthetic bioactive inhibitors of glycogen synthase kinase
Khan, I., Tantray, M. A., Alam, M. S., & Hamid, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.058 · Cited by 80
Kerr, F., Bjedov, I., & Sofola-Adesakin, O. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00297 · Cited by 80
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 80
Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?
Potenza, M. A., Sgarra, L., Desantis, V., Nacci, C., & Montagnani, M. (2021) · Antioxidants · doi:10.3390/antiox10081257 · Cited by 78
Li, J., Ma, S., Chen, J., Hu, K., Li, Y., Zhang, Z., Su, Z., Woodgett, J. R., Li, M., & Huang, Q. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00081 · Cited by 76
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Haghighijoo, Z., Zamani, L., Moosavi, F., & Emami, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113949 · Cited by 77
Translation Approach for Dentine Regeneration Using GSK-3 Antagonists
Zaugg, L. K., Banu, A., Walther, A. R., Chandrasekaran, D., Babb, R., Salzlechner, C., Hedegaard, M. A. B., Gentleman, E., & Sharpe, P. T. (2020) · Journal of Dental Research · doi:10.1177/0022034520908593 · Cited by 75
Metadata
- Authors
- Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., León, T., & del Ser, T.
- Affiliations
- University of Oxford (GB)
- Fundació ACE (ES)
- Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- Inserm (FR)
- University of Turku (FI)
- Instituto de Salud Carlos III (ES)
- Clinical Department, Noscira SA, Madrid, Spain
- Medical Department, Noscira SA, Madrid, Spain
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-03-03
- Volume
- 45
- Issue
- 1
- Pages
- 75-88
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1522284801
- Cited by
- 536
- References
- 47
- Citations by year
- 2026: 44 · 2025: 67 · 2024: 59 · 2023: 46 · 2022: 38 · 2021: 59 · 2020: 61 · 2019: 31 · 2018: 46 · 2017: 39 · 2016: 31 · 2015: 14
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10053)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tideglusib, Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Thiadiazoles, Amyloid beta-Peptides, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
